ACIU (AC Immune) Marketable Securities : $142.21 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is AC Immune Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. AC Immune's Marketable Securities for the quarter that ended in Mar. 2025 was $142.21 Mil.

AC Immune's annual Marketable Securities declined from Dec. 2022 ($97.68 Mil) to Dec. 2023 ($28.39 Mil) but then increased from Dec. 2023 ($28.39 Mil) to Dec. 2024 ($144.92 Mil).

AC Immune Marketable Securities Historical Data

The historical data trend for AC Immune's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AC Immune Marketable Securities Chart

AC Immune Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

73.17

125.95

97.68

28.39

144.92

AC Immune Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															53.81	138.24	148.11	144.92	142.21

AC Immune Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

AC Immune (NAS:ACIU) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

AC Immune Marketable Securities Related Terms

Thank you for viewing the detailed overview of AC Immune's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

AC Immune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (NAS:ACIU) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

IMR:Germany IMR:Germany

Address

EPFL Innovation Park, Building B, Lausanne, CHE, 1015

Website

https://www.acimmune.com

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.